Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver-Reference-Cited by-同舟云学术

Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver

Published:1985-01 Issue:4 Volume:15 Page:343-350
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Colombo T.¹,D'incalci M.¹,Donelli M. G.¹,Bartosek I.¹,Benfenati E.¹,Farina P.¹,Guaitani A.¹

Affiliation:

1. Istituto di Ricerche Farmacologiche ‘Mario Negri’, Via Eritrea, 62-20157, Milan, Italy

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.3109/00498258509045369

Reference21 articles.

1. ETOPOSIDE: A NEW ANTI-CANCER AGENT

2. Bartosek I., Guaitani A., Garattini. Isolated Liver Perfusion and its Applications, I. Bartosek, A. Guaitani, L. L. Miller. Raven Press, New York 1973; 63

3. Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice

4. Cure of Mice bearing Advanced Plasma Cell Tumours with Aniline Mustard : the Relationship between Glucuronidase Activity and Tumour Sensitivity

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Search for New and Novel Chemotherapeutics for the Treatment of Human Malignancies;Mini-Reviews in Medicinal Chemistry;2010-05-01

2. UDP-Glucuronosyltransferase 1A1 Is the Principal Enzyme Responsible for Etoposide Glucuronidation in Human Liver and Intestinal Microsomes: Structural Characterization of Phenolic and Alcoholic Glucuronides of Etoposide and Estimation of Enzyme Kinetics;Drug Metabolism and Disposition;2006-12-06

3. Pharmacokinetic Optimisation of Treatment with Oral Etoposide;Clinical Pharmacokinetics;2004

4. Glucuronidation of Etoposide in Human Liver Microsomes Is Specifically Catalyzed by UDP-Glucuronosyltransferase 1A1;Drug Metabolism and Disposition;2003-05-01

5. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations;Cancer Chemotherapy and Pharmacology;1994